COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,220 Articles (22,733 medRxiv, 8,487 bioRxiv)

Most recent first Previous |  Page 1111: Articles 11101-11110  | Next

Factors associated with COVID-19 vaccine acceptance and hesitancy among residents of Northern California jails
Liu, Y. E., Oto, J., Will, J., LeBoa, C., Doyle, A., Rens, N., Aggarwal, S., Kalish, I., Rodriguez, M., Sherif, B., Trinidad, C., del Rosario, M., Allen, S., Spencer, R., Morales, C., Chyorny, A., Andrews, J. R.
10.1101/2021.11.22.21266559 — Posted: 2021-11-24
Development and Performance verification of colloidal gold labeled SARS-CoV-2 antigen detection method for routine popular screening of COVID-19 with clinical samples in Poland and China
Guo, C., Yao, L., Chen, F., Zhang, C., Chen, W.
10.1101/2021.11.22.21266719 — Posted: 2021-11-24
The Failures of an Ideal COVID-19 Vaccine: A Simulation Study
Kosinski, R. J.
10.1101/2021.11.22.21266669 — Posted: 2021-11-24
Final sizes and durations of new COVID-19 pandemic waves in Ukraine and around the world predicted by generalized SIR model
Nesteruk, I.
10.1101/2021.11.22.21266683 — Posted: 2021-11-24
Simulating the impact of vaccination rates on the initial stages of a COVID-19 outbreak in New Zealand (Aotearoa) with a stochastic model
Watson, L. M.
10.1101/2021.11.22.21266721 — Posted: 2021-11-24 Discussion: Onsite
In vitro, classical complement activation differs by disease severity and between SARS-CoV-2 antigens
Lamerton, R. E., Marcial Juarez, E., Faustini, S. E., Perez-Toledo, M. E., Goodall, M., Jossi, S. E., Newby, M. L., Chapple, I., Dietrich, T., Veenith, T., Shields, A. M., Harper, L., Henderson, I. R., Rayes, J., Wraith, D. C., Watson, S. P., Crispin, M., Drayson, M. T., Richter, A. G., Cunningham, A. F.
10.1101/2021.11.22.21266681 — Posted: 2021-11-24
The role of multi-generational household clusters in COVID-19 in England
Thelwall, S., Zaidi, A., Nsonwu, O., Rice, W., Chudasama, D., Lamagni, T., Dabrera, G.
10.1101/2021.11.22.21266540 — Posted: 2021-11-24
In Vitro Nasal Tissue Model for the Validation of Nasopharyngeal and Mid-turbinate Swabs for SARS-CoV-2 Testing
Hartigan, D. R., Adelfio, M., Shutt, M. E., Jones, S. M., Patel, S., Marchand, J. T., McGuinness, P. D., Buchholz, B. O., Ghezzi, C. E.
10.1101/2021.11.22.21266713 — Posted: 2021-11-24
Serological responses to COVID-19 booster vaccine in England
Ireland, G., Whitaker, H., Ladhani, S. N., Baawuah, F., Subbarao, V., Linley, E., Warrener, L., O'Brien, M., Whillock, C., Moss, P., Ramsay, M. E., Amirthalingam, G., Brown, K. E.
10.1101/2021.11.22.21266692 — Posted: 2021-11-24
Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study
Neuhauser, H., Schaffrath Rosario, A., Butschalowsky, H., Haller, S., Hoebel, J., Michel, J., Nitsche, A., Poethko-Mueller, C., Pruetz, F., Schlaud, M., Steinhauer, H. W., Wilking, H., Wieler, L. H., Schaade, L., Liebig, S., Goesswald, A., Grabka, M. M., Zinn, S., Ziese, T.
10.1101/2021.11.22.21266711 — Posted: 2021-11-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).